Currently, there are no approved HDAC inhibitors specifically for ARDS; agents such as vorinostat, panobinostat, and valproic acid are FDA-approved for other indications, offering potential for drug repurposing in the context of severe lung inflammation [45]. Here, HDAC9 is linked to acute respiratory distress syndrome.